B7-BLOCKING AGENTS, ALONE OR IN COMBINATION WITH CYCLOSPORINE-A, INDUCE ANTIGEN-SPECIFIC ANERGY OF HUMAN-MEMORY T-CELLS
Citation
Yq. Zhang et al., B7-BLOCKING AGENTS, ALONE OR IN COMBINATION WITH CYCLOSPORINE-A, INDUCE ANTIGEN-SPECIFIC ANERGY OF HUMAN-MEMORY T-CELLS, The Journal of immunology, 158(10), 1997, pp. 4734-4740
Categorie Soggetti
Immunology
Journal title
The Journal of immunology
SICI code
0022-1767(1997)158:10<4734:BAAOIC>2.0.ZU;2-O
Abstract
T cell anergy refers to a functional state in which the cells are aliv
e but unable to produce IL-2 after appropriate triggering. Lack of CD2
8 costimulation through CD80 and CD86 molecules on APC might play a ca
usative role in anergy induction, as previously shown with T cell clon
es. We now developed a model of anergy induction in cultures of freshl
y isolated memory T cells. Addition of either CTLA-4Ig or blocking ant
i-CD80 and anti-CD86 mAbs, in combination with cyclosporin A, to cultu
res of PBMC with soluble Ag consistently resulted in Ag-specific unres
ponsiveness, as evidenced upon antigenic rechallenge. In most experime
nts, the presence of cyclosporin A was not required, and blocking the
B7-CD28 interaction during antigenic stimulation was sufficient to ind
uce unresponsiveness. Unresponsiveness was apparent at the level of T
cell proliferation as well as at the level of IL-2 and IFN-gamma produ
ction, and T cell responses to unrelated Ags were intact. Induction of
unresponsiveness correlated with lack of T cell proliferation in the
induction culture and could largely be prevented by supplementing the
induction cultures with rlL-2, indicating that lack of IL-2 was respon
sible for this altered functional state. Unresponsive T cells did not
suppress the proliferation of autologous T cells in response to origin
al or third-party Ags. On the other hand, culture with IL-2 and Ag cou
ld reverse established T cell unresponsiveness, pointing to anergy rat
her than deletion as the underlying mechanism. Anergy induction in fre
shly isolated memory T cells opens perspectives for treatment of autoi
mmune and allergic diseases.